Novartis’ troubles over the Zolgensma data manipulation incident show no sign of lessening. The company is on the defensive again after it emerged a senior manager sold almost $1 million worth ...

FDA granted an accelerated approval for Vanrafia for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Vanrafia can be ...

Since 2020, the global SMA treatment landscape has progressed, with three treatments now approved, according to Novartis. Along with Zolgensma – which made its debut in 2019 – Biogen has had ...

During an earnings call, the firm reported strong sales for Pluvicto and other precision medicines and elaborated on its US manufacturing plans.

Zolgensma is a prescription drug that’s used to treat spinal muscular atrophy (SMA) in young children. Zolgensma’s cost may depend on factors such as your child’s treatment plan and whether ...

The company uses the facility to manufacture its spinal muscular atrophy gene therapy, called Zolgensma. Last year, Novartis reported revenue from Zolgensma of $1.2 billion.

Novartis’ Durham facility produces Zolgensma, which treats spinal muscular atrophy, an inherited fatal disorder often referred to as SMA. In 2019, the Food and Drug Administration approved ...

The company uses the facility to manufacture its spinal muscular atrophy gene therapy, called Zolgensma. Novartis-owned firm picks Durham over Illinois, Ireland for 200 jobs Multibillion-dollar ...

Ad hoc announcement pursuant to Art. 53 LR Net sales grew +15% (cc1, +12% USD) with core operating income1 up +27% (cc, +23% USD) Sales growth driven by continued strong performance from Entresto ...